32 studies found for:    " June 13, 2012":" July 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 13, 2012":" July 13, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
Conditions: HIV Infection;   Healthy
Intervention:
2 Enrolling by invitation Positive Change Agents Program-Tanzania (Evaluation)
Condition: HIV Infection
Intervention: Behavioral: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
3 Recruiting Bone Health and Vitamin D Status
Conditions: Osteopenia;   Vitamin D Deficiency;   HIV Infection
Intervention:
4 Active, not recruiting BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
Condition: HIV
Intervention: Drug: efavirenz
5 Active, not recruiting MARCH Central Nervous System Substudy
Condition: HIV-1 Infection
Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors;   Drug: Arm 2 Maraviroc and Protease Inhibitors;   Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
6 Completed Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Condition: HIV-1 Infection
Interventions: Drug: Vacc-C5/GM-CSF;   Drug: Vacc-C5/Alhydrogel
7 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
8 Active, not recruiting Evaluation of Barriers to Postpartum Care in HIV Infected Women
Conditions: HIV Infection;   Pregnancy
Intervention: Other: questionaires and structured interviews
9 Active, not recruiting A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
Condition: HIV Infections
Interventions: Drug: MK-1439;   Drug: Efavirenz;   Drug: TRUVADA®
10 Completed
Has Results
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: TUMS® Ultra Strength;   Drug: MINTOX® Maximum Strength
11 Active, not recruiting Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
Condition: HIV Infections
Intervention: Drug: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
12 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pineal Gland Astrocytoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Anaplastic Thyroid Cancer;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Cancer;   Extra-adrenal Paraganglioma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Gastrinoma;   Glucagonoma;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Insular Thyroid Cancer;   Insulinoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Pancreatic Polypeptide Tumor;   Peripheral T-cell Lymphoma;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Tumor;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Islet Cell Carcinoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Pheochromocytoma;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Thyroid Cancer;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Gastrointestinal Carcinoid Tumor;   Regional Pheochromocytoma;   Small Intestine Lymphoma;   Somatostatinoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adult Soft Tissue Sarcoma;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Follicular Thyroid Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Melanoma;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Rectal Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Neuroendocrine Carcinoma of the Skin;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Colon Cancer;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Papillary Thyroid Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Colon Cancer;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Papillary Thyroid Cancer;   Stage IVB Rectal Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Papillary Thyroid Cancer;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: romidepsin;   Other: pharmacological study
13 Recruiting A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Condition: HIV-1 Infection
Interventions: Drug: Darunavir;   Drug: Etravirine;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Raltegravir;   Drug: Second line ART regimens are usually based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs);   Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available;   Other: SOC adherence versus SOC+CPI adherence
14 Recruiting Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
Conditions: HIV-1 Infection;   Pf Subclinical Parasitemia
Interventions: Drug: Lopinavir/ritonavir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz;   Drug: Nevirapine;   Drug: emtricitabine/tenofovir disoproxil fumarate;   Drug: trimethoprim/sulfamethoxazole
15 Completed Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM
Conditions: HIV Testing;   Linkage to Care
Intervention:
16 Unknown  Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings
Condition: HIV
Interventions: Other: EMR Only;   Other: EMR+CDSS
17 Unknown  A Couple-Based Relationship Strengthening HIV Intervention for Young Parents
Condition: HIV
Interventions: Behavioral: Relationship Strengthening HIV Prevention Intervention;   Behavioral: Parenting Program Intervention
18 Recruiting Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Blantyre, Malawi
Condition: HIV
Interventions: Drug: Standard of Care prophylaxis;   Drug: Chloroquine (CQ) prophylaxis
19 Active, not recruiting MARCH Renal Substudy
Conditions: Proteinuria;   HIV
Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors;   Drug: Arm 2 boosted protease inhibitors and maraviroc;   Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
20 Recruiting Randomized Control Trial of Family-Based HIV Prevention for Latinos
Conditions: HIV;   Sexually Transmitted Infections
Intervention: Behavioral: Latino STYLE

Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results
Indicates status has not been verified in more than two years